On June 25, QingSong Health rose 9.68% in regular trading, trading at HK$14.17/share, with turnover of HK$58.44 million. The rally was driven by a series of recent positive developments reinforcing market confidence in the companys AI-powered healthcare commercialization trajectory.

On the news front, the company recently signed a strategic cooperation agreement with Shanghai Pharma Holdings (Hunan) to build an intelligent rare disease screening and full-cycle health management system powered by its proprietary evidence-based medicine AI agent ZhengYuanFang. Simultaneously, QingSong Health entered a three-year strategic MOU with Basel Medical Group to jointly expand into Southeast Asian markets. Additionally, controlling shareholder Yang Yin voluntarily extended her share lock-up period to January 1, 2027, while the board resolved to repurchase up to HK$100 million in shares from the open market. The combined lock-up extension and buyback program effectively alleviates prior market concerns over post-lockup selling pressure, sustaining bullish momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)